恆瑞醫藥(600276.SH):子公司HRX0701片獲批開展臨牀試驗
格隆匯4月1日丨恆瑞醫藥(600276.SH)公佈,近日,江蘇恆瑞醫藥股份有限公司子公司山東盛迪醫藥有限公司收到國家藥品監督管理局核准簽發關於HRX0701片的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。
HRX0701片是公司開發的二肽基肽酶Ⅳ(DPP-4)抑制劑磷酸瑞格列汀與鹽酸二甲雙胍固定劑量複方製劑,通過兩種不同作用機制達到更好的降血糖作用。目前國內外已有多個同類複方產品獲批上市。經查詢,2020年DPP-4抑制劑與二甲雙胍複方製劑全球銷售額約為57.2億美元。截至目前,HRX0701片相關項目累計已投入研發費用約790萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.